Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance

CONCLUSIONSProstate‐specific antigen–based prostate cancer screening in the United States between the ages of 55 and 69 years, as recommended by the USPSTF, may be cost‐effective at a $100,000 threshold but only with a quadrennial screening frequency and with AS offered to all low‐risk men. Cancer 2017. © 2017 American Cancer Society.
Source: Cancer - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research